Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

17 de janeiro de 2021 atualizado por: Hanmi Pharmaceutical Company Limited

A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).

Visão geral do estudo

Status

Rescindido

Condições

Intervenção / Tratamento

Descrição detalhada

This is a single-arm, open-label, Phase 2 study to assess the anti-tumor efficacy of oral single agent HM61713 administered to patients with T790M-positive NSCLC after treatment with an EGFR-TKI as measured by objective response rate (ORR).

Tipo de estudo

Intervencional

Inscrição (Real)

162

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Alemanha
      • Berlin, Alemanha
        • Research Site
      • Homburg, Alemanha
        • Research Site
      • Leipzig, Alemanha
        • Research Site
      • München, Alemanha
        • Research Site
      • Ulm, Alemanha
        • Research Site
  • Austrália
      • Darlinghurst, Austrália
        • Research Site
      • Fitzroy, Austrália
        • Research Site
      • Frankston, Austrália
        • Research Site
      • Kogarah, Austrália
        • Research Site
      • St Albans, Austrália
        • Research Site
      • Woolloongabba, Austrália
        • Research Site
  • Canadá
      • Toronto, Canadá
        • Research Site
  • Espanha
      • Barcelona, Espanha
        • Research Site
      • Barcelona, Espanha
        • Research Site 2
      • Barcelona, Espanha
        • Research Site 3
      • Barcelona, Espanha
        • Research Site 4
      • La Coruna, Espanha
        • Research Site
      • Madrid, Espanha
        • Research Site
      • Madrid, Espanha
        • Research Site 2
      • Navarra, Espanha
        • Research Site
      • San Sebastian, Espanha
        • Research Site
      • Valencia, Espanha
        • Research Site
      • Valencia, Espanha
        • Research Site 2
  • Estados Unidos
    • California
      • Beverly Hills, California, Estados Unidos
        • Research Site
      • Burbank, California, Estados Unidos
        • Research Site
      • Los Angeles, California, Estados Unidos
        • Research Site
      • Los Angeles, California, Estados Unidos
        • Research Site 2
      • Montebello, California, Estados Unidos
        • Research Site
      • Orange, California, Estados Unidos
        • Research Site
      • San Diego, California, Estados Unidos
        • Research Site
    • Florida
      • Boca Raton, Florida, Estados Unidos
        • Research Site
    • Hawaii
      • Honolulu, Hawaii, Estados Unidos
        • Research Site
    • Illinois
      • Evanston, Illinois, Estados Unidos
        • Research Site
    • Maryland
      • Bethesda, Maryland, Estados Unidos
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos
        • Research Site
    • New Hampshire
      • Lebanon, New Hampshire, Estados Unidos
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos
        • Research Site
    • Washington
      • Washington, Washington, Estados Unidos
        • Research Site
  • Filipinas
      • Cebu, Filipinas
        • Research Site
    • Kalakhang Maynila
      • Makati, Kalakhang Maynila, Filipinas
        • Research Site
    • Manila
      • Pasig, Manila, Filipinas
        • Research Site
    • Metro Manila
      • Manila, Metro Manila, Filipinas
        • Research Site 2
      • Manila, Metro Manila, Filipinas
        • Research Site
  • Itália
      • Bergamo, Itália
        • Research Site
      • Bologna, Itália
        • Research Site
      • Catania, Itália
        • Research Site
      • Milano, Itália
        • Research Site
      • Rome, Itália
        • Research Site
  • Malásia
      • Kuala Lumpur, Malásia
        • Research Site
      • Kuantan, Malásia
        • Research Site
      • Kuching, Malásia
        • Research Site
    • Penang
      • George Town, Penang, Malásia
        • Research Site
  • Republica da Coréia
      • Cheongju-si, Republica da Coréia
        • Research Site
      • Goyang-si, Republica da Coréia
        • Research Site
      • Hwasun, Republica da Coréia
        • Research Site
      • Incheon, Republica da Coréia
        • Research Site
      • Seongnam-si, Republica da Coréia
        • Research Site 2
      • Seongnam-si, Republica da Coréia
        • Research Site
      • Seoul, Republica da Coréia
        • Research Site
      • Seoul, Republica da Coréia
        • Research Site 2
      • Seoul, Republica da Coréia
        • Research Site 3
      • Seoul, Republica da Coréia
        • Research Site 4
      • Seoul, Republica da Coréia
        • Research Site 5
      • Seoul, Republica da Coréia
        • Research Site 6
      • Seoul, Republica da Coréia
        • Research Site 7
      • Seoul, Republica da Coréia
        • Research Site 8
  • Taiwan
      • Kaohsiung, Taiwan
        • Research Site
      • Taichung, Taiwan
        • Research Site
      • Tainan, Taiwan
        • Research Site
      • Tainan, Taiwan
        • Research Site 2
      • Taipei, Taiwan
        • Research Site
      • Taipei, Taiwan
        • Research Site 2

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

20 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age: at least 20 years of age
  • Cytologically or histologically confirmed adenocarcinoma of locally advanced or metastatic NSCLC which is not amenable to curative surgery or radiotherapy
  • Radiologically confirmed disease progression after at least one line of treatment with an EGFR-TKI
  • At least one documented EGFR mutation which is known to be related with susceptibility to EGFR-TKIs (including G719X, exon 19 deletion, L858R, and L861Q)
  • World Health Organization (WHO) performance score of 0 to 1 with life expectancy of at least 3 months
  • Centrally confirmed T790M mutation positive tumor status from a tumor sample taken after confirmation of disease progression on the most recent anticancer treatment regimen
  • At least one lesion (excluding the brain), not previously irradiated that can be accurately measured per RECIST version 1.1
  • Adequate hematological and biological function
  • Females of child-bearing potential must agree to use adequate contraception and for 3 months after the last dose of study drug
  • Male patients should be documented to be sterile or agree to use barrier contraception
  • Recovery to ≤ Grade 1 or baseline of any toxicities, except for stable sensory neuropathy ≤ Grade 2 and alopecia

Exclusion Criteria:

  • Known history of hypersensitivity to active or inactive excipients of HM61713 or drugs with a similar chemical structure of HM61713
  • Previous treatment with anticancer therapies, EGFR-TKI, HM61713, or other drugs that target T790M-positive mutant EGFR with sparing of wild-type, investigational agent(s) within 28 days prior to the first administration of study drug, radiotherapy
  • Any non-study related significant surgical procedures within the past 28 days prior to the first administration of study drug
  • Spinal cord compression, leptomeningeal carcinomatosis or active symptomatic brain metastases
  • History of any other malignancy
  • Clinically significant uncontrolled condition(s)
  • Active or chronic pancreatitis
  • Anyone with cardiac abnormalities or history
  • Presence or history of ILD, drug-induced ILD, or presence of radiation pneumonitis
  • Pregnant or breast feeding
  • In the opinion of the investigator, the patient is an unsuitable candidate to receive HM61713

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: HM61713
HM61713 800 mg (2 x 400 mg tablets) once daily (QD)
Medicamento: HM61713
800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigator"s opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.
Outros nomes:
  • Olmutinibe

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Objective response rate (ORR)
Prazo: At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
To assess the anti-tumor efficacy of HM61713 as measured by objective response rate (ORR).
At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Disease control rate (DCR), defined as the proportion of patients with a documented CR, PR, and SD during the treatment cycles according to the RECIST version 1.1
Prazo: At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
To assess clinical efficacy of HM61713 regarding disease control rate (DCR).
At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
Duration of overall tumor response (DR), defined as the interval between the date of the first observation of tumor response (CR or PR) and the date of disease progression or death
Prazo: At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
To assess clinical efficacy of HM61713 regarding Duration of overall tumor response (DR).
At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
Progression-free survival (PFS), defined as the time from first administration of study drug to determination of tumor progression by RECIST version 1.1 or death due to any cause, whichever occurs first
Prazo: At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
To assess clinical efficacy of HM61713 regarding Progression-free survival (PFS).
At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
Overall survival (OS), defined as the time from first administration of study drug until death from any cause
Prazo: From first dose to end of study or date of death from any cause whichever came first, assessed up to 48 months
To assess clinical efficacy of HM61713 regarding Overall survival (OS).
From first dose to end of study or date of death from any cause whichever came first, assessed up to 48 months
Time to progression (TTP), defined as the time from first administration of study drug to determination of tumor progression by RECIST version 1.1
Prazo: At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
To assess clinical efficacy of HM61713 regarding Time to progression (TTP).
At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
Tumor shrinkage calculated as absolute change and percentage change from baseline in sum of tumor size at each assessment using RECIST tumor response
Prazo: At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
To assess clinical efficacy of HM61713 regarding tumor shrinkage.
At baseline and every 6 weeks from time of first dose until date of progression, assessed up to 12 months
Peak concentration (Cmax) of HM61713
Prazo: Pre-dose (-30 to 0 mins) and 1 hour (± 5 mins), 3, 4, 6 hours (± 10 mins) on Day 1 and Day 15 of Cycle 1 and pre-dose (-30 to 0 mins) only on Day 8 of Cycle 1 and Day 1 of Cycle 2 (Day 22)
To determine the pharmacokinetic (PK) profile of HM61713.
Pre-dose (-30 to 0 mins) and 1 hour (± 5 mins), 3, 4, 6 hours (± 10 mins) on Day 1 and Day 15 of Cycle 1 and pre-dose (-30 to 0 mins) only on Day 8 of Cycle 1 and Day 1 of Cycle 2 (Day 22)
Trough plasma concentration (Ctrough) of HM61713
Prazo: Pre-dose (-30 to 0 mins) and 1 hour (± 5 mins), 3, 4, 6 hours (± 10 mins) on Day 1 and Day 15 of Cycle 1 and pre-dose (-30 to 0 mins) only on Day 8 of Cycle 1 and Day 1 of Cycle 2 (Day 22)
To determine the pharmacokinetic (PK) profile of HM61713.
Pre-dose (-30 to 0 mins) and 1 hour (± 5 mins), 3, 4, 6 hours (± 10 mins) on Day 1 and Day 15 of Cycle 1 and pre-dose (-30 to 0 mins) only on Day 8 of Cycle 1 and Day 1 of Cycle 2 (Day 22)
Area under the plasma concentration time curve over the 24-hour dosing interval (AUC) of HM61713
Prazo: Pre-dose (-30 to 0 mins) and 1 hour (± 5 mins), 3, 4, 6 hours (± 10 mins) on Day 1 and Day 15 of Cycle 1 and pre-dose (-30 to 0 mins) only on Day 8 of Cycle 1 and Day 1 of Cycle 2 (Day 22)
To determine the pharmacokinetic (PK) profile of HM61713.
Pre-dose (-30 to 0 mins) and 1 hour (± 5 mins), 3, 4, 6 hours (± 10 mins) on Day 1 and Day 15 of Cycle 1 and pre-dose (-30 to 0 mins) only on Day 8 of Cycle 1 and Day 1 of Cycle 2 (Day 22)
Patient reported outcomes (PROs)
Prazo: At baseline and every 6 weeks from time of discontinuation, assessed up to 24 months
To assess patient reported outcomes (PROs) of health-related quality of life (HRQoL), disease/treatment-related symptoms of lung cancer, and general health status.
At baseline and every 6 weeks from time of discontinuation, assessed up to 24 months
ECG/QTc (absolute values and change from baseline)
Prazo: Adverse events will be collected from baseline until 28 days after the last dose
To evaluate the effect of HM61713 on the QT interval.
Adverse events will be collected from baseline until 28 days after the last dose
Incidence of reported AEs and abnormal laboratory tests (AEs will be assessed using the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 4).
Prazo: Adverse events will be collected from baseline until 28 days after the last dose
To assess the safety and tolerability of HM61713.
Adverse events will be collected from baseline until 28 days after the last dose
QTc interval as assessed by digital ECG with central reading. The QT interval will be rate-corrected using 3 methods: QTcF, QTcB and QTcS.
Prazo: Adverse events will be collected from baseline until 28 days after the last dose
To assess the safety and tolerability of HM61713.
Adverse events will be collected from baseline until 28 days after the last dose

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Hanmi Pharmaceutical Company Limited

Investigadores

  • Investigador principal: Keunchil Park, M.D., Ph.D, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea
  • Investigador principal: Pasi A. Jänne, M.D., Ph.D, Dana-Farber Cancer Institute, Boston, MA, USA

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

31 de agosto de 2015

Conclusão Primária (Real)

8 de dezembro de 2020

Conclusão do estudo (Real)

8 de dezembro de 2020

Datas de inscrição no estudo

Enviado pela primeira vez

22 de junho de 2015

Enviado pela primeira vez que atendeu aos critérios de CQ

25 de junho de 2015

Primeira postagem (Estimativa)

30 de junho de 2015

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de janeiro de 2021

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de janeiro de 2021

Última verificação

1 de janeiro de 2021

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • HM-EMSI-202
  • 2015-001435-21 (Número EudraCT)

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Ensaios clínicos em Câncer de Pulmão de Células Não Pequenas

Ensaios clínicos em HM61713

Pesquisar ensaios semelhantes

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

CROs by country

CROs in Mozambique

Condições

Doenças Raras

Intervenções de drogas

Suplementos Alimentares

Patrocinador / Colaboradores

Localizações

Se inscrever